DK Life Science Statistics
Total Valuation
DK Life Science has a market cap or net worth of KRW 142.65 billion. The enterprise value is 168.57 billion.
Market Cap | 142.65B |
Enterprise Value | 168.57B |
Important Dates
Earnings Date | n/a |
Ex-Dividend Date | n/a |
Share Statistics
DK Life Science has 15.99 million shares outstanding.
Current Share Class | 15.99M |
Shares Outstanding | 15.99M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 15.44% |
Owned by Institutions (%) | n/a |
Float | 3.81M |
Valuation Ratios
The trailing PE ratio is 32.19.
PE Ratio | 32.19 |
Forward PE | n/a |
PS Ratio | 1.07 |
PB Ratio | 1.14 |
P/TBV Ratio | 1.19 |
P/FCF Ratio | 45.06 |
P/OCF Ratio | 17.32 |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.29, with an EV/FCF ratio of 53.25.
EV / Earnings | 44.34 |
EV / Sales | 1.26 |
EV / EBITDA | 9.29 |
EV / EBIT | 13.87 |
EV / FCF | 53.25 |
Financial Position
The company has a current ratio of 2.34, with a Debt / Equity ratio of 0.35.
Current Ratio | 2.34 |
Quick Ratio | 1.68 |
Debt / Equity | 0.35 |
Debt / EBITDA | 2.43 |
Debt / FCF | 13.90 |
Interest Coverage | 4.96 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | n/a |
Return on Invested Capital (ROIC) | n/a |
Return on Capital Employed (ROCE) | 8.17% |
Revenue Per Employee | 1.33B |
Profits Per Employee | 38.02M |
Employee Count | 100 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
In the past 12 months, DK Life Science has paid 2.61 billion in taxes.
Income Tax | 2.61B |
Effective Tax Rate | 40.75% |
Stock Price Statistics
Beta (5Y) | n/a |
52-Week Price Change | n/a |
50-Day Moving Average | 9,397.00 |
200-Day Moving Average | n/a |
Relative Strength Index (RSI) | 40.13 |
Average Volume (20 Days) | 95,282 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, DK Life Science had revenue of KRW 133.30 billion and earned 3.80 billion in profits. Earnings per share was 277.14.
Revenue | 133.30B |
Gross Profit | 28.89B |
Operating Income | 12.15B |
Pretax Income | 6.42B |
Net Income | 3.80B |
EBITDA | 18.15B |
EBIT | 12.15B |
Earnings Per Share (EPS) | 277.14 |
Balance Sheet
The company has 18.09 billion in cash and 44.02 billion in debt, giving a net cash position of -25.92 billion or -1,620.99 per share.
Cash & Cash Equivalents | 18.09B |
Total Debt | 44.02B |
Net Cash | -25.92B |
Net Cash Per Share | -1,620.99 |
Equity (Book Value) | 125.27B |
Book Value Per Share | 7,832.96 |
Working Capital | 73.00B |
Cash Flow
In the last 12 months, operating cash flow was 8.24 billion and capital expenditures -5.07 billion, giving a free cash flow of 3.17 billion.
Operating Cash Flow | 8.24B |
Capital Expenditures | -5.07B |
Free Cash Flow | 3.17B |
FCF Per Share | 197.96 |
Margins
Gross margin is 21.67%, with operating and profit margins of 9.11% and 2.85%.
Gross Margin | 21.67% |
Operating Margin | 9.11% |
Pretax Margin | 4.81% |
Profit Margin | 2.85% |
EBITDA Margin | 13.61% |
EBIT Margin | 9.11% |
FCF Margin | 2.37% |
Dividends & Yields
DK Life Science does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | n/a |
Shareholder Yield | n/a |
Earnings Yield | 2.67% |
FCF Yield | 2.22% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | |
Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
DK Life Science has an Altman Z-Score of 2.9 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 2.9 |
Piotroski F-Score | 3 |